Zelboraf and Brain neoplasm - a phase IV clinical study of FDA data

Summary:

Brain neoplasm is reported as a side effect among people who take Zelboraf (vemurafenib), especially for people who are male, 60+ old, have been taking the drug for 2 - 5 years also take Cotellic, and have Malignant melanoma.

The phase IV clinical study analyzes which people have Brain neoplasm when taking Zelboraf. It is created by eHealthMe based on reports of 8,381 people who have side effects when taking Zelboraf from the FDA, and is updated regularly.

What is Zelboraf?

Zelboraf has active ingredients of vemurafenib. eHealthMe is studying from 8,392 Zelboraf users. Check the latest studies of Zelboraf.

What is Brain neoplasm?

Brain neoplasm (tumour of brain) is found to be associated with 688 drugs and 654 conditions by eHealthMe. Check the latest studies of Brain neoplasm.

On Aug, 03, 2026

8,381 people reported to have side effects when taking Zelboraf.
Among them, 49 people (0.58%) have Brain neoplasm.

Among these 49 people:

How long have people been on Zelboraf when they have Brain neoplasm? *

What is the gender of people who have Brain neoplasm when taking Zelboraf? *

female: 28.57 %
male: 71.43 %

What is the age of people who have Brain neoplasm when taking Zelboraf? *

What are other drugs people take besides Zelboraf? *

What are other side effects people have besides Brain neoplasm? *

Joint Pain: 11 people, 22.45%
Fatigue (feeling of tiredness): 10 people, 20.41%
Nausea (feeling of having an urge to vomit): 9 people, 18.37%
Diarrhea: 9 people, 18.37%
Rashes (redness): 8 people, 16.33%
Dizziness: 8 people, 16.33%
Muscle Aches (muscle pain): 7 people, 14.29%
Weight Decreased: 7 people, 14.29%
Melanocytic Naevus (a type of lesion that contains nevus cells (a type of melanocyte)): 5 people, 10.20%
Hyperkeratosis (thickening of the outer layer of the skin): 5 people, 10.20%

What are the existing conditions these people have? *

Malignant Melanoma (skin cancer rises from melancytes): 22 people, 44.90%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 12 people, 24.49%
Pain: 4 people, 8.16%
Depression: 2 people, 4.08%
High Blood Cholesterol: 2 people, 4.08%
Histiocytosis (a blood disease characterized by an abnormal multiplication of macrophages): 2 people, 4.08%
Type 2 Diabetes: 1 person, 2.04%
Joint Stiffness: 1 person, 2.04%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 1 person, 2.04%
Bipolar Disorder (mood disorder): 1 person, 2.04%

* Approximation only. Some reports may have incomplete information.

Do you take Zelboraf and have Brain neoplasm?

- Check whether Brain neoplasm is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zelboraf:

Zelboraf (8,392 reports)

Brain neoplasm treatments and more:

Brain neoplasm (13,044 reports)

Browse all side effects of Zelboraf:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Brain neoplasm:

Brain neoplasm (688 drugs)

Browse all the conditions that are associated with Brain neoplasm:

Brain neoplasm (654 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on vemurafenib (the active ingredients of Zelboraf) and Zelboraf (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.